NPCENeuroPace Inc

Nasdaq www.neuropace.com


$ 7.10 $ -0.29 (-3.92 %)    

Wednesday, 04-Sep-2024 15:59:45 EDT
QQQ $ 460.65 $ -1.20 (-0.26 %)
DIA $ 410.44 $ 0.17 (0.04 %)
SPY $ 550.83 $ -1.13 (-0.2 %)
TLT $ 98.96 $ 1.26 (1.29 %)
GLD $ 230.43 $ 0.14 (0.06 %)
$ 7.1
$ 7.29
$ 7.01 x 100
$ 7.10 x 100
$ 7.05 - $ 7.48
$ 5.75 - $ 18.15
25,297
na
207.3M
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 03-05-2024 12-31-2023 10-K
4 11-06-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 03-02-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-10-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 06-03-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-neuropace-maintains-18-price-target

Cantor Fitzgerald analyst Ross Osborn reiterates NeuroPace (NASDAQ:NPCE) with a Overweight and maintains $18 price target.

 wells-fargo-maintains-overweight-on-neuropace-lowers-price-target-to-15

Wells Fargo analyst Vik Chopra maintains NeuroPace (NASDAQ:NPCE) with a Overweight and lowers the price target from $20 to $15.

 neuropace-lifts-fy24-revenue-guidance-from-73m---77m-to-76m---78m-est-75899m

NeuroPace continues to expect revenue growth to be primarily driven by increasing sales of its RNS System and higher sales of D...

 neuropace-q2-2024-gaap-eps-026-beats-031-estimate-sales-19256m-beat-18297m-estimate

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by ...

 morgan-stanley-maintains-equal-weight-on-neuropace-lowers-price-target-to-8

Morgan Stanley analyst Drew Ranieri maintains NeuroPace (NASDAQ:NPCE) with a Equal-Weight and lowers the price target from $...

 cantor-fitzgerald-reiterates-overweight-on-neuropace-maintains-18-price-target

Cantor Fitzgerald analyst Ross Osborn reiterates NeuroPace (NASDAQ:NPCE) with a Overweight and maintains $18 price target.

 neuropace-maintains-fy24-revenue-guidance-of-73m-77m-est-75205m

Gross margin to range between 72% and 74%, Total operating expenses to range between $80 million and $84 million, including app...

 neuropace-q1-2024-gaap-eps-032-beats-033-estimate-sales-18124m-beat-17302m-estimate

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by ...

 wells-fargo-upgrades-neuropace-to-overweight-raises-price-target-to-20

Wells Fargo analyst Lawrence Biegelsen upgrades NeuroPace (NASDAQ:NPCE) from Equal-Weight to Overweight and raises the price...

 jp-morgan-maintains-overweight-on-neuropace-raises-price-target-to-17

JP Morgan analyst Robbie Marcus maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $9 to $17.

 cantor-fitzgerald-maintains-overweight-on-neuropace-raises-price-target-to-18

Cantor Fitzgerald analyst Ross Osborn maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $...

 morgan-stanley-maintains-equal-weight-on-neuropace-raises-price-target-to-13

Morgan Stanley analyst Drew Ranieri maintains NeuroPace (NASDAQ:NPCE) with a Equal-Weight and raises the price target from $...

 neuropace-provides-full-year-2024-revenue-guidance-of-73m-77m-est-74598m

Gross margin to range between 72% and 74%, Total operating expenses to range between $80 million and $84 million, including app...

 recap-neuropace-q4-earnings
Recap: NeuroPace Q4 Earnings
03/05/2024 21:35:06

 neuropace-q4-2023-gaap-eps-023-beats-032-estimate-sales-1801m-beat-1746m-estimate

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.32) by ...

 earnings-scheduled-for-march-5-2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...

 earnings-preview-neuropace
Earnings Preview: NeuroPace
03/04/2024 17:01:14

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION